Skip to main content
News & Articles

January 10, 2020 | Research

U of T’s Deep Genomics secures $40 million in financing for AI drug development platform: Betakit

Brendan Frey smiles, with hands clasped on a table.

Brendan Frey (PhD 1997) is the CEO of Deep Genomics and a professor in U of T's Faculty of Applied Science & Engineering (photo by Johnny Guatto)

Deep Genomics, an artificial intelligence-powered drug discovery start-up co-founded by University of Toronto professor and alumnus Brendan Frey (PhD 1997), recently raised $40 million in Series B funding, Betakit reports.

The latest round, led by Future Ventures and including investments from Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures, brings the startup’s total funding to date to $61 million.

Betakit notes that Deep Genomics in September “identified a new treatment target and corresponding drug candidate for Wilson disease,” a rare genetic disorder that causes an accumulation of copper in vital organs, which can be fatal if left untreated.

The capital will help Deep Genomics, which announced the financing last week, bring its Wilson disease program to the clinic, said Frey, a founding member of the Vector Institute for Artificial Intelligence and a professor in the department of electrical and computer engineering in the Faculty of Applied Science & Engineering. 

Read the story at Betakit

COVID-19 Update:

For community safety, in-person events are currently postponed or cancelled. Explore virtual events and resources for alumni on the #StayHome hub. Are you a 2020 graduate? Start your lifelong access. Have questions? Contact us.